Immunogenicity of booster vaccination with a virosomal hepatitis a vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine

Journal of Travel Medicine

Volumn 11, Issue 4, 2004, Pages 201-207

  Beck, Bernard R ^a   Hatz, Christoph F R ^a   Loutan, Louis ^b   Steffen, Robert ^c  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; ALUMINUM HYDROXIDE; HAVRIX 720; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; VIROSOME VACCINE;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BOOSTER VACCINATION; CHILD; CLINICAL TRIAL; DRUG BOOSTER DOSE; DRUG DOSE; DRUG TOLERABILITY; EDEMA; ENZYME IMMUNOASSAY; ERYTHEMA; FATIGUE; FEMALE; HEADACHE; HEPATITIS A; HUMAN; IMMUNITY; IMMUNOGENICITY; MALE; MULTICENTER STUDY; NAUSEA; NORMAL HUMAN; OPEN STUDY; PAIN; PRIMARY VACCINATION; PROTECTION; REVACCINATION; SEROLOGY; SEROPROTECTION; SINGLE DRUG DOSE; SKIN INDURATION; TRAVEL; VACCINATION; VOMITING;

EID: 4043142797     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.2310/7060.2004.19002     Document Type: Article

References (30)

1. Koff RS. Hepatitis A. Lancet 1998; 351:1643-1649.
2. Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev 2001; 14:38-58.
3. Van Herck K, Beutels P, Van Damme P, et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 2000; 60:1-7.
4. Fan P-C, Chang M-H, Lee P-I, et al. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine 1998; 16:232-235.
5. Holzer BR, Egger M. Hepatitis A vaccine. Curr Opin Infect Dis 1995; 8:186-190.
6. Holzer BR, Hatz C, Schmidt-Sissolak D, et al. Immunogenicity and adverse effects of inactivated virosome versus alum-absorbed hepatitis A: a randomized controlled trial. Vaccine 1996; 14:982-986.
7. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271:1328-1334.
8. Westblom TU, Gudipati S, DeRousse C, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule. J Infect Dis 1994; 169:996-1001.
9. Linglöf T, Van Hattum J, Kaplan KM, et al. An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA) in adults: safety, tolerability, and immunogenicity. Vaccine 2001; 19:3968-3971.
10. Hornick R, Tucker R, Kaplan KM, et al. A randomized study of a flexible booster dosing regimen of VAQTA in adults: safety, tolerability, and immunogenicity. Vaccine 2001; 19:4727-4731.
11. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR 1999; 48(RR-12):1-38.
12. Zurbriggen R, Novak-Hofer I, Seelig A, Glück R. IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Prog Lip Res 2000; 39:3-18.
13. Just M, Berger R, Drechsler H, et al. A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks. Vaccine 1992; 10:737-739.
14. Loutan L, Bovier P, Althaus B, Glück R. Inactivated virosome hepatitis A vaccine. Lancet 1994; 343:322-324.
15. Poovorawan Y, Theamboonlers A, Chumdermpadetsuk S, et al. Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais. Vaccine 1995; 13:891-893.
16. Ambrosch F, Wiedermann G, Jonas S, et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997; 15:1209-1213.
17. Van Damme P. Hepatitis A: how to match prevention strategies to changing epidemiology. Vaccine 2001; 19:999-1002.
18. Tanaka J. Hepatitis A shift in epidemiology in Latin America. Vaccine 2000; 18:S57-S60.
19. Cianciara J. Hepatitis A shift in epidemiology in Poland and Eastern Europe. Vaccine 2000; 18:S68-S70.
20. Willner IR, Uhl MD, Howard SC, et al. Serious hepatitis A: an analysis of patients hospitalised during an urban epidemic in the United States. Ann Intern Med 1998; 128:111-114.
21. Van Damme P, Banatvala J, Fay O, et al. Hepatitis A booster vaccination: is there a need? Lancet 2003; 362:1065-1071.
22. Glück R, Mischler R, Brantschen S, et al. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest 1992; 90:2491-2495.
23. Lea AP, Balfour JA. Virosomal hepatitis A vaccine (Strain RGSB). A preliminary review of its immunogenicity, protective efficacy and tolerability in at-risk populations. BioDrugs 1997; 7:232-248.
24. Landry P, Tremblay S, Darioli R, Genton B. Inactivated hepatitis A vaccine booster given ≥ 24 months after the primary dose. Vaccine 2001; 19:399-402.
25. Iwarson S, Lindh M, Widerström L. Excellent booster response 4-6 y after a single primary dose of an inactivated hepatitis A vaccine. Scand J Infect Dis 2002; 34:110-111.
26. Beck BR, Hatz C, Brönnimann R, Herzog C. Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminium-free hepatitis A vaccine. Clin Infect Dis 2003; 37:e126-e128.
27. Williams JL, Brüden DA, Cagle HH, et al. Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine 2003; 21:3208-3211.
28. Zuckerman JN, Kirkpatrick CT, Huang M. Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A. J Travel Med 1998; 5:18-22.
29. Bryan JP, Henry CH, Hoffinan AG, et al. Randomized, crossover, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 2001; 19:743-750.
30. Connor BA, Phair J, Sack D, et al. Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix. Clin Infect Dis 2001; 32:396-401.